Frontiers in allergy最新文献

{"title":"Breaking the cycle: a comprehensive exploration of topical steroid addiction and withdrawal.","authors":"Anish R Maskey, Akimi Sasaki, Manuel Sargen, Maureen Kennedy, Raj K Tiwari, Jan Geliebter, Bijan Safai, Xiu-Min Li","doi":"10.3389/falgy.2025.1547923","DOIUrl":"https://doi.org/10.3389/falgy.2025.1547923","url":null,"abstract":"<p><p>Topical steroid withdrawal (TSW) is a skin condition characterized by red burning, itchy, painful skin lesions, often accompanied by peeling, and cracking. Patients experience sleep disturbances due to intense itching, significantly impacting their quality of life. A majority of affected individuals develop secondary bacterial infection, marked by heavy colonization of <i>Staphylococcus aureus (S. aureus)</i> and alterations in the skin microbiome. TSW is described as a rebound effect following discontinuation of prolonged use of mid-to-high-potency topical corticosteroids. There exist no definitive diagnostic criteria for this entity, and it is often misdiagnosed as a flare-up of an underlying condition or a contact allergy. Despite numerous personal reports and experiences shared on online platforms, studies on TSW remain scarce in scientific literature. Recognizing and effectively managing this condition is critical for healthcare providers seeking to develop comprehensive management plans. These plans typically include supportive therapy for both physical and psychological symptoms, as well as the gradual tapering of corticosteroid use before complete discontinuation. This review aims to consolidate the existing knowledge on TSW, providing a comprehensive resource for its identification, management, and treatment. By enhancing understanding of TSW, this review seeks to support healthcare providers in implementing optimal management strategies and improving patient outcomes.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1547923"},"PeriodicalIF":3.3,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>In vitro</i> models to study viral-induced asthma exacerbation: a short review for a key issue.","authors":"Rémi Pereira De Oliveira, Clément Droillard, Gilles Devouassoux, Manuel Rosa-Calatrava","doi":"10.3389/falgy.2025.1530122","DOIUrl":"https://doi.org/10.3389/falgy.2025.1530122","url":null,"abstract":"<p><p>Asthma is a heterogenous inflammatory bronchial disease involving complex mechanisms, several inflammatory pathways, and multiples cell-type networks. Bronchial inflammation associated to asthma is consecutive to multiple aggressions on epithelium, such as microbiologic, pollutant, and antigenic agents, which are responsible for both T2 and non-T2 inflammatory responses and further airway remodeling. Because asthma physiopathology involves multiple crosstalk between several cell types from different origins (epithelial, mesenchymal, and immune cells) and numerous cellular effectors, no single and/or representative <i>in vitro</i> model is suitable to study the overall of this disease. In this short review, we present and discuss the advantages and limitations of different <i>in vitro</i> models to decipher different aspects of virus-related asthma physiopathology and exacerbation.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1530122"},"PeriodicalIF":3.3,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11987631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Basophil activation test and lymphocyte transformation test in cefuroxime-induced anaphylactic reactions.","authors":"Andreas Glässner, Diana Dubrall, Gerda Wurpts, Philipp Deck, Günther Weindl, Caspar A Heubach, Amir S Yazdi, Bernhardt Sachs","doi":"10.3389/falgy.2025.1532775","DOIUrl":"https://doi.org/10.3389/falgy.2025.1532775","url":null,"abstract":"<p><strong>Introduction: </strong>Cefuroxime allergy may present as a delayed-type reaction or as an immunoglobulin (Ig)E-mediated immediate-type anaphylactic reaction. The basophil activation test (BAT) is a diagnostic tool for cefuroxime-induced immediate-type reactions, whereas the lymphocyte transformation test (LTT) is typically applied in delayed-type drug allergy. This study aimed to compare the results of the BAT and LTT in 15 patients with cefuroxime-induced anaphylactic reactions considered as confirmed. The pharmacoepidemiological part aimed to analyze spontaneous reports of cefuroxime-associated anaphylactic reactions in the European adverse drug reaction database (EudraVigilance).</p><p><strong>Methods: </strong>In EudraVigilance, 668 reports of cefuroxime-associated anaphylactic reactions for the European Economic Area (EEA) between 2010 and 2023 were analyzed, with 182 (27.2%) of these reports originating from Germany. The BAT and the LTT were performed according to standard protocols. Except for one patient, all BAT were performed prior to the skin tests, whereas all LTT were performed thereafter.</p><p><strong>Results: </strong>Almost all reports were classified as serious (EEA, 99.3%; Germany, 98.9%). In 60.8% (EEA) and 66.9% (Germany) of reports with respective information, the reaction occurred after intravenous administration. BAT was performed in 12 of 15 patients (3/12 positive; sensitivity 25%), while LTT was performed in all 15 patients (7/15 positive; sensitivity 46.7%).</p><p><strong>Conclusions: </strong>Our analysis highlights the importance of cefuroxime-associated anaphylactic reactions, as almost all of the spontaneous reports were classified as serious. Neither a negative BAT nor LTT can rule out a sensitization in cefuroxime-induced anaphylactic reactions.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1532775"},"PeriodicalIF":3.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Acari Hypothesis, VII: accounting for the comorbidity of allergy with other contemporary medical conditions, especially metabolic syndrome.","authors":"Andrew C Retzinger, Gregory S Retzinger","doi":"10.3389/falgy.2025.1537467","DOIUrl":"https://doi.org/10.3389/falgy.2025.1537467","url":null,"abstract":"<p><p>The Acari Hypothesis proposes that vector-active acarians, i.e., mites and ticks, are the etiologic agents responsible for most, if not all, allergies. A corollary of The Hypothesis posits allergies are now more prevalent because contemporary hygienic practices remove from skin elements of sweat that otherwise deter acarians. Because the antimicrobial activity of sweat extends beyond acarians, disruption/removal of sweat on/from skin must enable aberrant microbial colonization, possibly potentiating comorbid conditions assignable to the aberrant microbial colonist(s). Allergy is strongly comorbid with metabolic syndrome. Available evidence links the principal features of metabolic syndrome to <i>Staphylococcus aureus</i>, an organism influenced significantly by constituents of sweat. Thus, the removal of sweat predisposes to both allergy and metabolic syndrome. Indeed, the \"immune-compromised\" state brought upon by contemporary hygienic practices likely accounts for the comorbidity of many contemporary medical conditions, examples of which are highlighted.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1537467"},"PeriodicalIF":3.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study protocol for a randomized double-blinded placebo-controlled trial on mepolizumab for patients with chronic rhinosinusitis with nasal polyps, NSAID exacerbated respiratory disease and asthma.","authors":"Annina Lyly, Johanna Sahlman, Karoliina Pajala, Maija Salminen, Saara Sillanpää, Jura Numminen, Tanzeela Hanif, Anu Laulajainen-Hongisto, Mika Mäkelä, Paula Kauppi, Iiris Kangasniemi, Markus Lilja, Sari Hammaren-Malmi, Paula Virkkula, Sanna Toppila-Salmi","doi":"10.3389/falgy.2025.1568081","DOIUrl":"10.3389/falgy.2025.1568081","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nose and paranasal sinuses that significantly impactshealth-related quality of life. Nonsteroidal anti-inflammatory drug (NSAID) -exacerbated respiratory disease (N-ERD) affects approximately one fifth of CRSwNP patients. N-ERD and asthma increase the risk of uncontrolled CRSwNP as measured by frequent sinus surgeries and rescue treatment. Compared to non-N-ERD patients, those with N-ERD also have higher risk of asthma exacerbations, severe allergic reactions, and anosmia. Mepolizumab is a humanized monoclonal anti-IL-5 antibody shown to be effective in treating severe eosinophilic asthma and CRSwNP. While evidence suggests that mepolizumab alleviates respiratory symptoms in N-ERD patients, placebo-controlled studies remain limited.</p><p><strong>Methods: </strong>The aim of this prospective randomized, placebo-controlled, multicenter study is to investigate whether mepolizumab reduces polyp size, symptom scores, and exacerbations more than placebo during the 16-week treatment period in patients with uncontrolled CRSwNP, N-ERD and asthma. Additionally, we will examine the effect of mepolizumab on drug dosage and lung and nasal function and evaluate predictive biomarkers.We will recruit 120 patients with N-ERD, nasal polyposis and asthma in three centers in Finland. Patients will be randomized into two 16-week treatment groups in 1:1 ratio (placebo or mepolizumab 100 mg every 4 weeks). The study lasts for 6 months, including recruitment visit 2-4 weeks before randomization. Participants will attend 6 visits, during four of which they will receive a subcutaneous injection of the study product. At each visit, patient-reported outcome tests, clinical examination, airway function tests, and nasal, blood, urine, and stool samples will be conducted.</p><p><strong>Discussion: </strong>The efficacy of the 16-week anti-IL-5-treatment in this severe patient group will be analyzed, as well as possible predictive biomarkers.</p><p><strong>Clinical trial registration: </strong>ClinicalTrials.gov ID NCT04823585. Registered on 28.3.2021.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1568081"},"PeriodicalIF":3.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between vaccination, viral antibodies, and asthma prevalence in the U.S.: insights from NHANES (1999-2020).","authors":"Zonghui Yang, Jia Guo, Manman Cheng, Youwen Zhang, Zhi Chen, Jie Wen, Fenglian Shan","doi":"10.3389/falgy.2025.1456934","DOIUrl":"10.3389/falgy.2025.1456934","url":null,"abstract":"<p><strong>Objective: </strong>This investigation aimed to explore the differences in asthma prevalence among various demographic groups in the U.S., focusing on factors related to vaccination and viral antibodies.</p><p><strong>Methods: </strong>The study analyzed data from 37,445 individuals collected through the National Health and Nutrition Examination Survey between 1998 and 2020. Employing weighted sampling methods, the analysis considered the stratification and clustering typical of the survey's design. It particularly examined how age, race, income, smoke, education, and gender factors influence both the prevalence and severity of asthma.</p><p><strong>Results: </strong>This study aims to elucidate disparities in asthma prevalence across the U.S. population by examining the roles of demographic characteristics and factors related to vaccination and viral antibodies. It revealed a significant correlation between asthma prevalence and patient demographics, including age, gender, income, smoke, education, and race. We found that asthma patients were mostly found in participants with lower economic level (2.7 vs. 2.87). Non-Hispanic black women age exhibited a higher likelihood of asthma, at 17.7%, compared to non-Hispanic whites and Mexican Americans. Asthma prevalence peaks between the ages of 20 and 30 and has shown a rising trend over the years. Regarding vaccinations, hepatitis A, hepatitis B, pneumococcal, and HPV vaccines were associated with an increased risk of asthma. Conversely, patients testing positive for hepatitis A virus and core hepatitis B virus antibodies demonstrated a lower prevalence of asthma. Additionally, asthmatic patients showed lower average measles virus and rubella antibodies levels, at 0.53 and 3.32, respectively, compared to non-asthmatic individuals. Notably, asthma incidence was lower in herpesvirus I-positive patients (OR: 0.895, CI, 0.809%-0.991%), while herpesvirus II-positive patients displayed a higher incidence of asthma (OR: 1.102, CI, 0.974%-1.246%).</p><p><strong>Conclusion: </strong>The study findings underscore the significant prevalence of asthma and its correlation with population demographics, vaccination rates, and serum viral antibodies. These results highlight the importance of implementing tailored public health interventions.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1456934"},"PeriodicalIF":3.3,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11968725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a <i>post hoc</i> analysis from the ANANKE study.","authors":"Luisa Brussino, Maria Aliani, Elena Altieri, Pietro Bracciale, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Laura Malerba, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Maria D'Amato","doi":"10.3389/falgy.2025.1501196","DOIUrl":"10.3389/falgy.2025.1501196","url":null,"abstract":"<p><strong>Introduction: </strong>Severe eosinophilic asthma (SEA) often co-occurs with chronic rhinosinusitis with nasal polyps (CRSwNP), worsening asthma symptoms. Earlier studies have shown that benralizumab improves asthma outcomes with greater efficacy if patients present CRSwNP.</p><p><strong>Methods: </strong>This <i>post hoc</i> analysis of the ANANKE study (NCT04272463) reports data on the long-term effectiveness of benralizumab between SEA patients with and without CRSwNP (<i>N</i> = 86 and <i>N</i> = 75, respectively) treated for up to 96 weeks.</p><p><strong>Results: </strong>Before benralizumab initiation, CRSwNP patients displayed longer SEA duration, greater oral corticosteroid (OCS) use and blood eosinophil count. After 96 weeks of treatment, the annual exacerbation rate (AER) decreased in both groups, with CRSwNP patients achieving considerable reductions than No-CRSwNP patients (severe AER dropped by 100% and 95.6%, respectively). While lung function improvement was comparable at week 96, CRSwNP patients showed a faster response to benralizumab, with a rise of forced expiratory volume in 1 s (FEV₁) at 16 weeks that was maintained throughout the study. Median OCS daily dose decreased to 0.0 mg in both groups at 96 weeks, but benralizumab OCS-sparing effect was faster in CRSwNP patients (median OCS dose was 0.0 mg and 2.5 mg in CRSwNP and No-CRSwNP patients respectively, at 48 weeks). Although asthma control test (ACT) median scores were comparable, greater proportions of CRSwNP patients displayed well-controlled asthma (ACT ≥ 20) than No-CRSwNP patients at all time points.</p><p><strong>Discussion: </strong>These findings show benralizumab long-term effectiveness in SEA patients with and without CRSwNP, highlighting its superior and faster-acting benefits on asthma outcomes in presence of CRSwNP.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1501196"},"PeriodicalIF":3.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Respiratory symptoms, sensitisation and occupational exposure in the shrimp processing industry.","authors":"Fikirte Debebe Zegeye, Pål Graff, Miriam Grgic, Steen Mollerup, Anani Komlavi Afanou, Berit Elisabeth Bang, Karl-Christian Nordby, Anne Straumfors, Johanna Samulin Erdem","doi":"10.3389/falgy.2025.1520576","DOIUrl":"10.3389/falgy.2025.1520576","url":null,"abstract":"<p><strong>Introduction: </strong>Shellfish processing workers are highly susceptible to respiratory illnesses such as allergies and asthma. This study examined respiratory symptoms and biomarkers of allergy and asthma in Norwegian shrimp processing plant workers and evaluated allergenic and irritant protein exposures in the workplace.</p><p><strong>Material and methods: </strong>The study included 35 shrimp processing workers and 21 controls. Respiratory symptoms were assessed via questionnaire; blood samples were analysed for allergy and asthma biomarkers and specific IgE levels. Air samples were analysed for protein levels and composition.</p><p><strong>Results: </strong>Shrimp processing workers had four to five times higher odds of reporting acute upper and chronic lower respiratory symptoms than the controls. They also had significantly higher plasma levels of IL4, CCL20, CSF2 and MMP12, with 11% of the exposed workers showing elevated levels of shrimp and crab specific IgE. Furthermore, exposed workers showed increased plasma levels of SFTPD and CHI3L1 post-shift. The median total protein exposure was 6 µg/m³, with peaks up to 66 µg/m³ in the cooking and peeling department. Total protein levels were correlated with CCL20, IL13, and basophil counts. Ninety-five shrimp proteins were identified, including seven known and eight potential allergens. Tropomyosin levels were generally high, particularly in the cooking and peeling department.</p><p><strong>Conclusion: </strong>Shrimp workers had a higher prevalence of respiratory symptoms and biomarkers of allergy and asthma. The work environment contained tropomyosin and other allergenic proteins as well as irritants, highlighting the need for protective measures, especially in the cooking and peeling departments.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1520576"},"PeriodicalIF":3.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11967198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum: Gut microbiome features in pediatric food allergy: a scoping review.","authors":"Margherita Farnetano, Laura Carucci, Serena Coppola, Franca Oglio, Antonio Masino, Marica Cozzolino, Rita Nocerino, Roberto Berni Canani","doi":"10.3389/falgy.2025.1588779","DOIUrl":"https://doi.org/10.3389/falgy.2025.1588779","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/falgy.2024.1438252.].</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1588779"},"PeriodicalIF":3.3,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food allergen introduction practices and parent/caregiver attitudes based on family history of food allergy.","authors":"Hunter G Smith, Sai Nimmagadda, Ruchi S Gupta, Christopher M Warren","doi":"10.3389/falgy.2025.1562667","DOIUrl":"10.3389/falgy.2025.1562667","url":null,"abstract":"<p><strong>Background: </strong>The National Institute of Allergy and Infectious Disease (NIAID) addendum guidelines for primary prevention of peanut allergy1 provide recommendations regarding peanut introduction, and a recent consensus statement highlighted the importance of timely introduction of other commonly allergenic solids, and the role of family history as a risk factor.2ObjectiveTo determine whether children in households with a food allergic parent/caregiver or sibling have different rates of being fed commonly allergenic solids during the first year of life than children lacking this family history.</p><p><strong>Methods: </strong>A pretested survey was administered between January-February 2021 to a U.S. sample of 3,062 parents/caregivers of children born since the NIAID Addendum guidelines. Survey-weighted chi-square statistics and logistic regression models tested the independence of key variables across strata of interest before and after covariate adjustment.</p><p><strong>Results: </strong>Peanut, almond, shellfish, and other tree nuts are more likely to be introduced to children with one or more food-allergic caregivers. Respondents with food-allergic parents (39.3%) and siblings with FA (35.8%) were more familiar with the 2017 NIAID guidelines compared to parents (12.9%) and siblings without FA (12.7%).</p><p><strong>Conclusion: </strong>Findings suggest that respondents with food-allergic parents and siblings are more likely to have many of the most prevalent allergens introduced at younger ages, which could be due to knowledge related to the NIAID-sponsored guidelines and other national guidance, but that even among these higher-risk families overall rates of \"early\" introduction during infancy still remain relatively low.</p>","PeriodicalId":73062,"journal":{"name":"Frontiers in allergy","volume":"6 ","pages":"1562667"},"PeriodicalIF":3.3,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11961653/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}